Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

846 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Design and conduct of early clinical studies of immunotherapy agent combinations: recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies.
Smoragiewicz M, Bogaerts J, Calvo E, Marabelle A, Perrone A, Seymour L, Shalabi A, Siu LL, Tabernero J, Giaccone G; task force on Methodology for the Development of Innovative Cancer Therapies. Smoragiewicz M, et al. Among authors: tabernero j. Ann Oncol. 2018 Nov 1;29(11):2175-2182. doi: 10.1093/annonc/mdy398. Ann Oncol. 2018. PMID: 30202892 Free article. Review.
Starting the fight in the tumor: expert recommendations for the development of human intratumoral immunotherapy (HIT-IT).
Marabelle A, Andtbacka R, Harrington K, Melero I, Leidner R, de Baere T, Robert C, Ascierto PA, Baurain JF, Imperiale M, Rahimian S, Tersago D, Klumper E, Hendriks M, Kumar R, Stern M, Öhrling K, Massacesi C, Tchakov I, Tse A, Douillard JY, Tabernero J, Haanen J, Brody J. Marabelle A, et al. Among authors: tabernero j. Ann Oncol. 2018 Nov 1;29(11):2163-2174. doi: 10.1093/annonc/mdy423. Ann Oncol. 2018. PMID: 30295695 Free PMC article.
ESMO-Magnitude of Clinical Benefit Scale version 1.1.
Cherny NI, Dafni U, Bogaerts J, Latino NJ, Pentheroudakis G, Douillard JY, Tabernero J, Zielinski C, Piccart MJ, de Vries EGE. Cherny NI, et al. Among authors: tabernero j. Ann Oncol. 2017 Oct 1;28(10):2340-2366. doi: 10.1093/annonc/mdx310. Ann Oncol. 2017. PMID: 28945867 Free article.
New drug development in digestive neuroendocrine tumors.
Durán I, Salazar R, Casanovas O, Arrazubi V, Vilar E, Siu LL, Yao J, Tabernero J. Durán I, et al. Among authors: tabernero j. Ann Oncol. 2007 Aug;18(8):1307-13. doi: 10.1093/annonc/mdm009. Epub 2007 Feb 13. Ann Oncol. 2007. PMID: 17301070 Free article. Review.
Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors.
Markman B, Tabernero J, Krop I, Shapiro GI, Siu L, Chen LC, Mita M, Melendez Cuero M, Stutvoet S, Birle D, Anak Ö, Hackl W, Baselga J. Markman B, et al. Among authors: tabernero j. Ann Oncol. 2012 Sep;23(9):2399-2408. doi: 10.1093/annonc/mds011. Epub 2012 Feb 22. Ann Oncol. 2012. PMID: 22357447 Free article. Clinical Trial.
846 results